7/9/2009

Novacta Biosystems secured more than $21 million in a financing round led by Celtic Pharma's second fund. The company will use the funding to advance the development of its line of hospital superbug-focused antibiotics, called "lantibiotics." Drugs being developed include treatments for Clostridium difficile and methicillin-resistant Staphylococcus aureus.

Related Summaries